BioMS Medical Corp., a biotech company, engages in the development and commercialization of therapeutic technologies with emphasis on the treatment of Multiple Sclerosis (MS). The company has three subsidiaries, BioMS Technology Corp. (BioMS Tech), BioMS Technology U.S. Corp. and BioMS Technology International Limited. The company has obtained a worldwide license to a proprietary technology developed at the MS Patient Care and Research Clinic at the University of Alberta for the treatment of MS. The technology, dirucotide (formally named MBP8298), is a synthetic myelin basic protein peptide comprised of 17 amino acids which is intravenously injected (every six months) into MS patients as a therapeutic treatment. The company is conducting late-stage clinical trials and one open-label trial for dirucotide in secondary progressive MS. The company focuses on advancing the clinical development of its product Dirucotide for the treatment of multiple sclerosis. It is in the process of conducting four clinical trials with Dirucotide. The MAESTRO-01 trial is, a pivotal Phase II/III, multi-centre, double blind, placebo-controlled trial designed to evaluate the safety and efficacy of Dirucotide in patients with secondary progressive multiple sclerosis (SPMS). HYC750 BioMS Tech held a worldwide license to technology from the University of Alberta, which involves a method for mobilizing hematopoetic cells in humans. History BioMS Medical Corp. was founded in 1998. The company was formerly known as EPS Capital Corp. and changed its name to BioMS Medical Corp. in 2001.
gdi integrated facility serv
Edmonton, AB T6E 6G4
|No competitor information is available for GDI.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact GDI INTEGRATED FACILITY SERV, please visit www.medwellcapital.com. Company data is provided by Capital IQ. Please use this form to report any data issues.